Moleculin gets Canadian patent allowance for Annamycin manufacturing process; term to 2040

Moleculin Biotech, Inc.

CIPO issued notice of allowance for patent application 3,142,510 covering preliposomal Annamycin lyophilizate preparation.
Patent expected to issue in coming months; base term extends to June 2040, subject to regulatory extension.
Company already holds issued U.S. and allowed European patents for Annamycin; additional applications pending globally.
CEO states this strengthens global IP portfolio for Annamycin as a non-cardiotoxic anthracycline for AML and STS lung mets.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.